13F Holdings
中文EN

NUWE Nuwellis, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1506492 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.3%
TTM net income YoY16.9%
TTM EPS YoY197.4%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR—

Margins

Gross margin70.8%
Operating margin-135.8%
Net margin-152.8%
FCF margin-136.6%
EBITDA margin-134.2%

Returns

ROE-200.1%
ROA-128.4%
ROIC (approx.)-815.9%
Asset turnover0.84x

Leverage & solvency

Liabilities / assets26.7%
Debt / equity0.00x
Current ratio3.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-13.6%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$8.27M$8.74M$8.86M$8.54M$7.92M
Cost of revenue$3.15M$3.06M$3.88M$3.79M$3.43M
Gross profit$5.12M$5.68M$4.98M$4.75M$4.49M
R&D expense$2.71M$3.21M$5.42M$4.34M$4.98M
SG&A expense$13.52M$13.46M$17.19M$17.58M$19.04M
Operating income-$11.11M-$10.99M-$17.63M-$17.17M-$19.53M
Pretax income-$17.52M-$11.16M-$20.20M-$14.52M-$19.55M
Income tax$5,000$5,000$8,000$9,000$9,000
Net income-$17.52M-$11.16M-$20.21M-$14.53M-$19.55M
EBITDA-$10.91M-$10.68M-$17.27M-$16.80M-$19.04M
EPS (basic)-25.39-353.30-360.06-83.55-285.36
EPS (diluted)-25.39-353.30-360.06-83.55-285.36
Weighted avg. shares (diluted)690,14531,60156,126173,84669,000
Balance sheet
Cash & equivalents$1.08M$5.09M$3.80M$17.74M$8.74M
Short-term investments——$0$569,000$15.46M
Receivables$1.49M$1.73M$1.95M$1.41M$750,000
Inventory$1.91M$1.72M$2.00M$2.66M$2.84M
Current assets$5.19M$8.86M$8.21M$22.77M$28.13M
PP&E, net$368,000$478,000$728,000$980,000$1.19M
Intangibles$0————
Total assets$6.12M$9.86M$9.77M$24.67M$30.42M
Current liabilities$3.03M$2.56M$3.17M$4.69M$3.31M
Total liabilities$3.49M$3.33M$6.56M$12.32M$4.47M
Shareholders' equity$2.62M$6.53M$2.99M$12.36M$25.95M
Shares outstanding5,342104,142161,925536,394105,376
Cash flow statement
Operating cash flow-$10.81M-$9.59M-$17.94M-$15.15M-$17.84M
Capital expenditure$90,000$60,000$149,000$122,000$219,000
Free cash flow-$10.90M-$9.65M-$18.09M-$15.27M-$18.06M
Investing cash flow-$90,000-$60,000$330,000$14.73M-$15.72M
Financing cash flow$6.94M$10.96M$3.68M$9.42M$27.87M
Depreciation & amortization$200,000$310,000$362,000$372,000$488,000
Stock-based compensation$127,000$478,000$670,000$862,000$1.31M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.